Trial to Examine the Effect of Natural Anti- Obesity Agent (Phaseolus Vulgaris) Among Women of Lahore

This double-blind randomized placebo-controlled trial will test the hypothesis that administration of Phaseolus Vulgaris supplementation to women in Lahore, Pakistan, who are overweight will induce the weight loss (Primary outcome) and changes in body composition (Waist circumference) secondary outcome.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Overweight and Obesity Body Weight Body Weight Changes Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms Weight Loss

Age range

18 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Akhuwat Medical Centre, Lahore, Punjab Province, Pakistan

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

BMI ranges from 25-40
Consistently stable body weight for at least 6 months
Good general health
No ongoing drug treatment for weight reduction
Commitment to avoid any changes in lifestyle throughout the test period
Age between 18-45 years
Women resident of Lahore

Exclusion criteria

Pregnant or breast-feeding females
People with Type 2 diabetes
People with any other chronic diseases
Weight reduction treatment during the 6 months prior to the study

Treatment and study plan

Phaseolus Vulgaris

Dietary Supplement

Weight loss

Placebo

Dietary Supplement

Placebo

Primary outcomes

Body weight

Time frame: 3 months

change in body weight

Sponsors and collaborators

Lead sponsor

Hafiza Aisha Sadiqa

Other

Collaborators

University of the Punjab

Registry information

Official study title

A Randomized Double Blind Study to Examine the Effect of Natural Anti-obesity Agent Among Women of Lahore

Acronym: PVE-AO

Important dates

Study start: 2022
Primary completion: 2023
Study completion: 2023
First posted: Jul 11, 2022
Registry last updated: Apr 30, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed